Evolent Health Stock Plummets to New 52-Week Low of $6.49

Evolent Health, Inc. has reached a new 52-week low, trading at USD 6.49 on November 4, 2025. This marks a significant decline for the microcap company, which has seen its stock price plummet by 72.64% over the past year, contrasting sharply with the S&P 500's performance of 19.89% during the same period. The company's financial metrics reveal a challenging landscape. Evolent Health has reported negative results for three consecutive quarters, with a pre-tax profit of USD -7.73 million, reflecting a staggering decline of 355.12%. Additionally, the net profit stands at USD -6.9 million, down 311.27%. The operating cash flow has also reached a low of USD -33.32 million, indicating ongoing financial strain. With a market capitalization of USD 1,151 million, Evolent Health operates within the miscellaneous industry. The company's return on equity is currently at -10.28%, and it has a price-to-book ratio of 1.28. These figures highlight the company's struggles in generating profitability and maintaining investor confidence amidst a backdrop of consistent underperformance against market benchmarks.